Neurodegenerative Diseases and Dementia
Pathology leading to continues neuronal death
Neurodegenerative diseases are pathophysiological situations that lead to the death of neuronal cells. No cure is available for these disease conditions.
Early Diagnosis is the Key
Early detection is only way to prevent disease progression
Sadly, noticeable symptoms of neurodegenerative disease are observed only after a significant loss of neuronal density. As neurons do not have regeneration capacity, it is considered “too late” when the first symptoms are observed.
We Have Advanced Technology
Non-invasive SIMOA based platform
Pre-symptomatic biomarkers associated with neurodegenerative diseases were previously only quantifiable from cerebrospinal fluid. Now with advanced single-molecule based array, we can effectively diagnose disease from blood samples.
ASSAY SERVICES
INTERVENTION THERAPY
Once neurodegeneration is diagnosed before the symptoms are observed. An intervention therapy can drastically improve the life quality of the patient by delaying or inhibiting pathological progression.
WHY IS INTERVENTION THERAPY BETTER?
Neurons lack regeneration capacity
It is known that neuronal cells are unable to regenerate. Therefore, symptomatic neurodegeneration is irreversible.
​
No effective cure
Although, several medical drugs are available for the treatment of neurodegenerative disorders yet none is considered effective.
​
Does not solely depend on drugs
Compound based therapeutics are known to cause side effects. Lifestyle interventions if effective are considered superior.
​
WE CAN PROVIDE INDIVIDUALIZED INTERVENTION THERAPY STEPS
ADDITIONAL SERVICES
DRUG DISCOVERY COMPANIES
Identification of novel drug efficacy using brain scan technology to identify disease progression is expansive. Blood-based prognostic biomarkers will reduce the net cost of clinical research.
CLINICAL RESEARCH CENTERS
Identification of novel drug efficacy using brain scan technology to identify disease progression is expansive. Blood-based prognostic biomarkers will reduce the net cost of clinical research.
CLIINCAL DIAGNOSTIC CENTERS
Individuals identified at high risk of neurodegenerative disorders may conduct annual checkups for asymptomatic biomarkers to ensure early identification and better treatment.
PHYSICAL EXAMINATION CLINICS
Individuals identified at high risk of neurodegenerative disorders may conduct annual checkups for asymptomatic biomarkers to ensure early identification and better treatment.
